Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163.

The hemoglobin scavenger receptor CD163 is exclusively expressed in the monocytic lineage and preferentially in tissue resident macrophages of the M2 phenotype and in macrophages in sites of inflammation and tumor growth. In the present study we have designed liposomes specifically targeting CD163 by hydrophobic linkage of CD163-binding monoclonal antibodies to polyethylene glycol-coated liposomes ('stealth liposomes'). Targeting to the endocytic CD163 protein greatly increased the uptake of liposomes in CD163 transfected cells and macrophages as visualized by confocal microscopy and flow cytometry of cells exposed to CD163 targeting liposomes loaded with calcein. Strong cytotoxic effects were seen in CD163-expressing human monocytes by using the chemotherapeutic agent doxorubicin as cargo of the liposomes. In conclusion, the use of stealth liposomes modified to recognize CD163 is a potential way to target drugs to macrophages that support inflammatory and malignant processes.

[1]  S. Lee,et al.  Quantitative analysis of total macrophage content in adult mouse tissues. Immunochemical studies with monoclonal antibody F4/80 , 1985, The Journal of experimental medicine.

[2]  M. Kurrer,et al.  Soluble hemoglobin–haptoglobin scavenger receptor CD163 as a lineage‐specific marker in the reactive hemophagocytic syndrome , 2005, European journal of haematology.

[3]  R. Lutter,et al.  Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. , 2009, Arthritis and rheumatism.

[4]  M. Hope,et al.  Contact hypersensitivity: a simple model for the characterization of disease-site targeting by liposomes. , 1999, Biochimica et biophysica acta.

[5]  R. Schiffelers,et al.  Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. , 2008, Neoplasia.

[6]  Theresa M Allen,et al.  Advantages of liposomal delivery systems for anthracyclines. , 2004, Seminars in oncology.

[7]  S. Moestrup,et al.  Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. , 2004, Arthritis and rheumatism.

[8]  P. Wallace,et al.  Endotoxin induces rapid metalloproteinase‐mediated shedding followed by up‐regulation of the monocyte hemoglobin scavenger receptor CD163 , 2002, Journal of leukocyte biology.

[9]  P. Tak,et al.  Macrophage Subsets in Immune-Mediated Inflammatory Disease: Lessons from Rheumatoid Arthritis, Spondyloarthritis, Osteoarthitis, Behçet’s Disease and Gout , 2010 .

[10]  P. Low,et al.  Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. , 1994, The Journal of biological chemistry.

[11]  T. Allen,et al.  Pharmacokinetics of stealth versus conventional liposomes: effect of dose. , 1991, Biochimica et biophysica acta.

[12]  G. Burmester,et al.  Macrophages in rheumatoid arthritis , 2000, Arthritis research.

[13]  R. Voegeli,et al.  A monoclonal antibody to a novel differentiation antigen on human macrophages associated with the down-regulatory phase of the inflammatory process. , 1987, Experimental cell biology.

[14]  V. Torchilin Antibody-modified liposomes for cancer chemotherapy , 2008, Expert opinion on drug delivery.

[15]  J. Calvert,et al.  CD163 Expression Confers Susceptibility to Porcine Reproductive and Respiratory Syndrome Viruses , 2007, Journal of Virology.

[16]  W. Jessup,et al.  The macrophage in atherosclerosis: modulation of cell function by sterols , 1999, Journal of leukocyte biology.

[17]  A. Palmer,et al.  Liposomes surface conjugated with human hemoglobin target delivery to macrophages , 2012, Biotechnology and bioengineering.

[18]  L. Zhang,et al.  Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.

[19]  J. Enghild,et al.  A Unique Loop Extension in the Serine Protease Domain of Haptoglobin Is Essential for CD163 Recognition of the Haptoglobin-Hemoglobin Complex* , 2007, Journal of Biological Chemistry.

[20]  R. Schiffelers,et al.  Investigation into the Role of Tumor-Associated Macrophages in the Antitumor Activity of Doxil , 2008, Pharmaceutical Research.

[21]  A. Lamprecht,et al.  Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases , 2010, Journal of The Royal Society Interface.

[22]  V. Torchilin Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[23]  T. Langmann,et al.  The Scavenger Receptor CD163: Regulation, Promoter Structure and Genomic Organization , 2000, Pathobiology.

[24]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[25]  E. Jordanova,et al.  Detection of M2-macrophages in uveal melanoma and relation with survival. , 2011, Investigative ophthalmology & visual science.

[26]  A. Sica,et al.  A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. , 2009, Blood.

[27]  P. Gómez-Puertas,et al.  Expression of porcine CD163 on monocytes/macrophages correlates with permissiveness to African swine fever infection , 2003, Archives of Virology.

[28]  T. K. van den Berg,et al.  The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. , 2009, Blood.

[29]  S. Moestrup,et al.  Tumor necrosis factor -converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163 , 2010 .

[30]  K. Mann,et al.  A two-component drug delivery system using Her-2-targeting thermosensitive liposomes , 2009, Journal of drug targeting.

[31]  Martine De Vos,et al.  Cartilage-derived morphogenetic protein-1 and -2 are endogenously expressed and stimulate proteoglycan synthesis in healthy and osteoarthritic human articular chondrocytes , 2001, Arthritis Research.

[32]  J C Stewart,et al.  Colorimetric determination of phospholipids with ammonium ferrothiocyanate. , 1980, Analytical biochemistry.

[33]  H. Segal,et al.  Uptake of free hemoglobin by rat liver parenchymal cells. , 1984, Biochemical and biophysical research communications.

[34]  J. Fonseca,et al.  Macrophage subpopulations in rheumatoid synovium: reduced CD163 expression in CD4+ T lymphocyte-rich microenvironments. , 2002, Arthritis and rheumatism.

[35]  A. Allison,et al.  The macrophage as a secretory cell in chronic inflammation , 1976, Agents and Actions.

[36]  H. Møller,et al.  Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Moestrup,et al.  Comparative assessment of the recognition of domain-specific CD163 monoclonal antibodies in human monocytes explains wide discrepancy in reported levels of cellular surface CD163 expression. , 2011, Immunobiology.

[38]  T. K. van den Berg,et al.  CD163‐positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation , 2005, Glia.

[39]  P. Guyre,et al.  TGF‐β regulation of human macrophage scavenger receptor CD163 is Smad3‐dependent , 2004 .

[40]  A. Mantovani,et al.  The origin and function of tumor-associated macrophages. , 1992, Immunology today.

[41]  A. Sica,et al.  Tumor promotion by tumor-associated macrophages. , 2007, Advances in experimental medicine and biology.

[42]  S. McCarthy,et al.  A monocyte/macrophage antigen recognized by the four antibodies GHI/61, Ber-MAC3, Ki-M8 and SM4. , 1992, Immunology.

[43]  A. Puig-Kröger,et al.  Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. , 2009, Cancer research.

[44]  B. Aggarwal,et al.  A Previously Unrecognized Protein-Protein Interaction between TWEAK and CD163: Potential Biological Implications1 , 2007, The Journal of Immunology.

[45]  Nalin Rastogi,et al.  Secretion of cytokines by human macrophages upon infection by pathogenic and non-pathogenic mycobacteria. , 2000, Microbial pathogenesis.

[46]  T. K. van den Berg,et al.  The rat macrophage scavenger receptor CD163: expression, regulation and role in inflammatory mediator production. , 2006, Immunobiology.

[47]  G. Berry Thermodynamic and Conformational Properties of Polystyrene. I. Light‐Scattering Studies on Dilute Solutions of Linear Polystyrenes , 1966 .

[48]  D. Mosser,et al.  The many faces of macrophage activation , 2003, Journal of leukocyte biology.

[49]  V. Torchilin,et al.  p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. , 2001, Biochimica et biophysica acta.

[50]  Yi-Chen Lin,et al.  Tumor-associated macrophages: the double-edged sword in cancer progression. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  D. Baeten,et al.  Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy , 2005, Arthritis research & therapy.

[52]  P. Högger,et al.  Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteine-rich family. , 1999, Biochemical and biophysical research communications.

[53]  R. Crofton,et al.  The origin, kinetics, and characteristics of the kupffer cells in the normal steady state , 1978, The Journal of experimental medicine.

[54]  T. Langmann,et al.  Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro‐ and antiinflammatory stimuli , 2000, Journal of leukocyte biology.

[55]  H. Yanagie,et al.  Liposomes Bearing Polyethyleneglycol-Coupled Transferrin with Intracellular Targeting Property to the Solid Tumors In Vivo , 2001, Pharmaceutical Research.

[56]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[57]  S. Moestrup,et al.  Identification of the haemoglobin scavenger receptor , 2001, Nature.

[58]  G. Kuttan,et al.  Role of macrophages in tumour progression. , 2009, Immunology letters.

[59]  Y. Mahida The key role of macrophages in the immunopathogenesis of inflammatory bowel disease , 2000 .

[60]  S. Moestrup,et al.  CD163: a regulated hemoglobin scavenger receptor with a role in the anti‐inflammatory response , 2004, Annals of medicine.

[61]  L. Boon,et al.  Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. , 2004, American journal of clinical pathology.

[62]  S. Moestrup,et al.  The macrophage CD163 surface glycoprotein is an erythroblast adhesion receptor. , 2007, Blood.

[63]  J. Orenstein,et al.  The macrophage in HIV infection. , 2001, Immunobiology.